Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Evaluate the Safety and Effectiveness of an Immunobiological Drug (Anti SARS-CoV-2) in the Treatment of Coronavirus Disease 2019 (CoViD-19)

NCT04913779 is registered in ClinicalTrials.gov with Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran as lead sponsor.

NCT NCT04913779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04913779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Evaluate the Safety and Effectiveness of an Immunobiological Drug (Anti SARS-CoV-2) in the Treatment of Coronavirus Disease 2019 (CoViD-19)
Lead sponsor
Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran
Phase
Phase 2/3
Overall status
Unknown status
Start date
June 1, 2021
Completion date
December 31, 2021
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pneumonia, covid-19 respiratory infection, covid19